Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: Rationale and design of the HoT-PE Trial

Stefano Barco, Mareike Lankeit, Harald Binder, Sebastian Schellong, Michael Christ, Jan Beyer-Westendorf, Daniel Duerschmied, Rupert Bauersachs, Klaus Empen, Matthias Held, Martin Schwaiblmair, Cândida Fonseca, David Jiménez, Cecilia Becattini, Kurt Quitzau, Stavros Konstantinides

Research output: Contribution to journalArticle

25 Citations (Scopus)

Fingerprint Dive into the research topics of 'Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: Rationale and design of the HoT-PE Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences